vs
Apellis Pharmaceuticals, Inc.（APLS）与Liberty Broadband Corp（LBRDA）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是Apellis Pharmaceuticals, Inc.的1.3倍（$261.0M vs $199.9M），Liberty Broadband Corp净利率更高（146.7% vs -29.5%，领先176.2%），Liberty Broadband Corp同比增速更快（6.1% vs -5.9%），Liberty Broadband Corp自由现金流更多（$37.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 4.3%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
APLS vs LBRDA — 直观对比
损益表 — Q4 FY2025 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $261.0M |
| 净利润 | $-59.0M | $383.0M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 15.7% |
| 净利率 | -29.5% | 146.7% |
| 营收同比 | -5.9% | 6.1% |
| 净利润同比 | -62.2% | 96.4% |
| 每股收益（稀释后） | $-0.40 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | — | ||
| Q2 25 | $178.5M | $261.0M | ||
| Q1 25 | $166.8M | $266.0M | ||
| Q4 24 | $212.5M | $263.0M | ||
| Q3 24 | $196.8M | $262.0M | ||
| Q2 24 | $199.7M | $246.0M | ||
| Q1 24 | $172.3M | $245.0M |
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | — | ||
| Q2 25 | $-42.2M | $383.0M | ||
| Q1 25 | $-92.2M | $268.0M | ||
| Q4 24 | $-36.4M | $291.0M | ||
| Q3 24 | $-57.4M | $142.0M | ||
| Q2 24 | $-37.7M | $195.0M | ||
| Q1 24 | $-66.4M | $241.0M |
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | 15.7% | ||
| Q1 25 | -50.0% | 16.2% | ||
| Q4 24 | -12.3% | 4.9% | ||
| Q3 24 | -24.0% | 11.5% | ||
| Q2 24 | -14.7% | 8.5% | ||
| Q1 24 | -36.0% | 11.4% |
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | — | ||
| Q2 25 | -23.6% | 146.7% | ||
| Q1 25 | -55.3% | 100.8% | ||
| Q4 24 | -17.1% | 110.6% | ||
| Q3 24 | -29.2% | 54.2% | ||
| Q2 24 | -18.9% | 79.3% | ||
| Q1 24 | -38.5% | 98.4% |
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | — | ||
| Q2 25 | $-0.33 | $2.68 | ||
| Q1 25 | $-0.74 | $1.87 | ||
| Q4 24 | $-0.30 | $2.04 | ||
| Q3 24 | $-0.46 | $0.99 | ||
| Q2 24 | $-0.30 | $1.36 | ||
| Q1 24 | $-0.54 | $1.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $180.0M |
| 总债务越低越好 | — | $3.1B |
| 股东权益账面价值 | $370.1M | $10.4B |
| 总资产 | $1.1B | $16.6B |
| 负债/权益比越低杠杆越低 | — | 0.30× |
8季度趋势，按日历期对齐
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | $180.0M | ||
| Q1 25 | $358.4M | $226.0M | ||
| Q4 24 | $411.3M | $163.0M | ||
| Q3 24 | $396.9M | $168.0M | ||
| Q2 24 | $360.1M | $73.0M | ||
| Q1 24 | $325.9M | $108.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $3.1B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | — | $3.8B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | — | $3.6B | ||
| Q1 24 | $93.1M | $3.6B |
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | — | ||
| Q2 25 | $156.3M | $10.4B | ||
| Q1 25 | $164.2M | $10.1B | ||
| Q4 24 | $228.5M | $9.8B | ||
| Q3 24 | $237.1M | $9.5B | ||
| Q2 24 | $264.3M | $9.3B | ||
| Q1 24 | $266.7M | $9.1B |
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $821.4M | $16.6B | ||
| Q1 25 | $807.3M | $17.0B | ||
| Q4 24 | $885.1M | $16.7B | ||
| Q3 24 | $901.9M | $16.3B | ||
| Q2 24 | $904.5M | $16.0B | ||
| Q1 24 | $831.9M | $15.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.30× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.39× | ||
| Q1 24 | 0.35× | 0.40× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $91.0M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $37.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 14.2% |
| 资本支出强度资本支出/营收 | 0.1% | 20.7% |
| 现金转化率经营现金流/净利润 | — | 0.24× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-49.0M |
8季度趋势，按日历期对齐
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | — | ||
| Q2 25 | $4.4M | $91.0M | ||
| Q1 25 | $-53.4M | $78.0M | ||
| Q4 24 | $19.4M | $1.0M | ||
| Q3 24 | $34.1M | $24.0M | ||
| Q2 24 | $-8.3M | $27.0M | ||
| Q1 24 | $-133.0M | $52.0M |
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | — | ||
| Q2 25 | $4.4M | $37.0M | ||
| Q1 25 | $-53.4M | $13.0M | ||
| Q4 24 | $19.3M | $-63.0M | ||
| Q3 24 | — | $-36.0M | ||
| Q2 24 | $-8.4M | $-35.0M | ||
| Q1 24 | $-133.3M | $-9.0M |
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | — | ||
| Q2 25 | 2.5% | 14.2% | ||
| Q1 25 | -32.0% | 4.9% | ||
| Q4 24 | 9.1% | -24.0% | ||
| Q3 24 | — | -13.7% | ||
| Q2 24 | -4.2% | -14.2% | ||
| Q1 24 | -77.3% | -3.7% |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | 20.7% | ||
| Q1 25 | 0.0% | 24.4% | ||
| Q4 24 | 0.0% | 24.3% | ||
| Q3 24 | 0.0% | 22.9% | ||
| Q2 24 | 0.0% | 25.2% | ||
| Q1 24 | 0.2% | 24.9% |
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
LBRDA
暂无分部数据
